argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized bas

argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that A

August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global

Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected

August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a g

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Ho

Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector s

I upgrade argenx to BUY with a $1,050 price target, citing sustained VYVGART growth, label expansion

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises th

argenx SE (ARGX) M&A Call Transcript

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Global immunology pioneer Argenx SE (NASDAQ:ARGX) on Monday struck a definitive agreement to purchas

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expa

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at appr

Baird analyst Colleen Kusy maintains argenx (NASDAQ:ARGX) with a Neutral and raises the price tar

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

argenx (Euronext and Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, I

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a discip

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune

AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovatio

Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a discip

Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and raises t

RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the pri

Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and raises the price ta

argenx delivered a Q2 marked by surging profitability, robust cash generation, and operational lever

Citizens analyst Jason Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and lowers

argenx SE (ARGX) Q2 2026 Earnings Call Transcript

argenx (NASDAQ:ARGX) released second-quarter financial results and hosted an earnings call on Thursd

argenex NASDAQ: ARGX reported what executives described as one of its strongest quarters to date, dr

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

Belgian-Dutch immunology company argenx said on ​Thursday global sales of its lead ‌drug Vyvgart jum

argenx (NASDAQ:ARGX) reported quarterly earnings of $7.32 per share which beat the analyst consensus

Citigroup analyst Samantha Semenkow maintains argenx (NASDAQ:ARGX) with a Buy and raises the pric

RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the pri

B of A Securities analyst Tazeen Ahmad maintains argenx (NASDAQ:ARGX) with a Buy and raises the p

HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myosi

HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maint

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and rais

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain

argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the liv

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the